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Karthikeshwar Kasirajan, MD, Ross Milner, MD, Thomas F. Dodson, MD, Atef A. Salam, MD, and
Elliot L. Chaikof, MD, PhD, Atlanta, Ga
Objective: This study was conducted to identify risk factors for late mortality after thoracic endovascular aortic repair
(TEVAR).
Methods: A retrospective analysis of consecutive TEVAR was conducted. Medical record review, telephone contact, or
query of the Social Security Death Index was used to determine 30-day and late survival. Late mortality was assessed with
respect to patient characteristics at the time of the initial treatment, preoperative laboratory values, pathology, clinical
presentation, and treatment adjuncts. Significant univariate predictors of death were entered into a multivariate Cox
proportional hazards model.
Results: From 1998 to 2009, 252 patients (149 men; mean age, 68 years) underwent TEVAR for degenerative thoracic
aortic aneurysm (TAA, n 143), type B dissection (n 62), mycotic aneurysm (n 13), traumatic disruption (n 12),
penetrating ulcer or intramural hematoma (n  10), anastomotic pseudoaneurysm (n  4), or other pathology (n  8).
The 30-day mortality was 9.5%, with stroke or spinal cord injury in 5.6%. Mean follow-up was 22  22 months.
Kaplan-Meier mean survival was 53 months. Predictors of late mortality by univariate analysis included age (P < .01),
cardiac arrhythmia (P  .03), chronic obstructive pulmonary disease (P  .05), aneurysm diameter (P < .01), rupture
(P< .01), debranching (P .02), leukocytosis (white blood cell count > 10.0 103/L; P< .01), albumin, (P< .01),
and creatinine > 1.7 mg/dL (P  .01). Multivariate predictors of mortality included rupture (hazard ratio [HR], 3.10;
95% confidence interval [CI], 1.02-9.44; P  .03), debranching (HR, 2.20; 95% CI, 1.09-4.24; P  .03), preoperative
leukocytosis (HR, 1.23; 95% CI, 1.09-1.39; P .001), and aneurysm diameter (HR, 1.02; 95% CI, 1.01-1.03; P .04).
Subgroup analysis of patients undergoing TEVAR for asymptomatic, nonruptured TAA demonstrated that debranching
(HR, 2.47; 95% CI, 1.13-5.39; P .02), White blood cell count (HR, 1.19; 95% CI, 1.01-1.40; P< .04), and aneurysm
diameter (HR, 1.03; 95% CI, 1.01-1.05, P < .01) remain independently predictive of late mortality.
Conclusions: Preoperative leukocytosis, aneurysm diameter, and concurrent debranching independently predict late
mortality irrespective of clinical presentation and may assist in risk stratification. (J Vasc Surg 2010;52:549-55.)The safety and efficacy of thoracic endovascular aortic
repair (TEVAR) has been established for a variety of diverse
thoracic aortic pathologies.1 Nonetheless, the appropriate-
ness of TEVAR is not fully defined for any given patient
because few risk factors for adverse outcomes and death
have been identified. Data are lacking regarding the long-
term durability of TEVAR, compounding the difficulty of
deciding upon whom and when to intervene for thoracic
aortic pathology.1,2 Single-center reports of all-cause mor-
tality 1 year after TEVAR are highly variable, ranging from
4% to 39%.2
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doi:10.1016/j.jvs.2010.04.059Improved preoperative risk stratification remains criti-
cal to refining indications for treatment and optimizing
outcomes.1-4 Multicenter U.S. Food and Drug Adminis-
tration (FDA)-sponsored clinical trials may fail to predict
the true morbidity and mortality of TEVAR after dissemi-
nation of this technology into the community, because the
number of enrolled patients is limited and use is restricted
to those whomeet specific enrollment criteria.5-8 Registries
may better reflect the scope of aortic pathology treated in
routine clinical practice, although such analyses are limited
by use of self-reported data that lack sufficient comprehen-
siveness to accurately assess preoperative risk factors and
postoperative morbidity and late death.9
A strong association has been demonstrated between
all-cause mortality and white blood cell (WBC) count,
independent of other risk factors, for patients with acute
coronary syndrome and peripheral arterial disease.10,11
These data suggest that other vascular syndromes, such as
aneurysmal disease, may display a similar association be-
tween leukocytosis and late mortality, given that all of these
conditions represent an inflammatory-mediated pathologic
process of the vascular wall, with a high preponderance of
underlying coronary artery disease.12-14 The purpose of
this study was to identify baseline risk factors for all-cause
mortality after TEVAR. In particular, we sought to identify
the role of preoperative leukocytosis, anemia, and throm-
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sought to identify those preoperative risk factors that most
strongly predicted all-cause mortality.
METHODS
This was a single-center retrospective review of consec-
utive patients undergoing TEVAR in the Division of Vas-
cular Surgery at Emory University Hospital between De-
cember 1998 and February 2009. Institutional Review
Board approval was obtained for this study before data
collection and analysis. Each patient’s vital status and
follow-up was confirmed by a review of the computerized
hospital records, direct patient telephone contact, or by
query of the Social Security Death Index (SSDI, http://
ssdi.rootsweb.com). Additional baseline data were supple-
mented from electronic medical records and archived im-
ages.
The thoracic aortic pathology of each patient was clas-
sified as one of the following: degenerative aneurysm, aortic
dissection, penetrating aortic ulcer or intramural hema-
toma, mycotic aneurysm, traumatic pseudoaneurysm or
transection, anastomotic pseudoaneurysm, or other pathol-
ogy, such as Kommerell diverticulum, “floating” intra-
aortic thrombi, or restenosis of a prior aortic coarctation
repair.1,2,9
Demographics, laboratory values, symptoms, and
aortic characteristics. Data collected included the age at
the time of implantation, gender, and medical comorbidi-
ties, including chronic obstructive pulmonary disease
(COPD), coronary artery disease (CAD), congestive heart
failure (CHF), hypertension, hypercholesterolemia, pe-
ripheral arterial disease (PAD), diabetes mellitus (DM), and
end-stage renal disease. Also recorded was a history of a
connective tissue disorder, cancer, tobacco abuse (former,
current, or none), myocardial infarction (MI), cardiac ar-
rhythmia, coronary artery bypass grafting (CABG), percu-
taneous coronary intervention (PCI), stroke, and concur-
rent abdominal aortic aneurysm (AAA) or prior AAA repair.
The use of a 3-hydroxy 3-methylglutaryl coenzyme A
inhibitor (statin), an angiotensin-converting enzyme inhib-
itor (ACE-I), an angiotensin receptor blocker (ARB), a
-blocker, or an antiplatelet agent (aspirin or clopidogrel)
was documented.
Baseline laboratory values collected include WBC
count (103 cells/L), hemoglobin (g/dL), hematocrit
(%), platelet count (103cells/L), serum creatinine (mg/
dL), and serum albumin (g/dL). WBC count was dichot-
omized between patients with baseline values lower and
higher than 10.0  103 cells/L. Serum creatinine was
also dichotomized between patients with baseline values
lower and higher than 1.7 mg/dL. All laboratory studies
were obtained 7 days before the procedure, with the
values closest to the day of operation chosen if multiple
values were present.
The presence of symptoms (pain, hoarseness, dyspha-
gia, hemoptysis), presentation (asymptomatic or ruptured),
and maximum aneurysm or pseudoaneurysm diameter
listed in the electronic record were recorded.Procedural data. The decisions to perform TEVAR,
which stent graft type, and need for concurrent procedures
(conduits, debranching procedures) were based on the
operator’s assessment of the clinical and anatomic features
in conjunction with detailed patient counseling. The en-
dograft devices used during the study period included TAG
(W.L. Gore, Scottsdale, Ariz), TX2 (Cook Inc, Blooming-
ton, Ind), Talent (Medtronic, Santa Rosa, Calif), and Val-
iant (Medtronic, Santa Rosa, Calif). The individual opera-
tor decided on the number of components to deploy as well
as use of adjunctive therapies, such as aortic cuffs, Palmaz
stents (Cordis, Miami Lakes, Fla), and renal or iliac stents.
Endograft placement was performed by femoral artery
exposure or through an iliac conduit, as described previ-
ously.1,5-8
Spinal drainage. Preprocedural spinal drains were
placed at the discretion of the operator. In most cases,
drains were placed if the patient met one of the following
conditions: (1) prior abdominal aortic surgery (open or
endovascular), (2) concurrent, planned coverage of 50%
of the thoracic aorta, or (3) planned coverage of the T9-
T12 segment. Other less consistent indications included
occlusion (planned or chronic) of one or both hypogastric
arteries or planned coverage of the left subclavian artery.
Drains were not placed in the instance of a ruptured aneu-
rysm. Drains were placed postoperatively if the patient
began to present symptoms of spinal cord ischemia (SCI).
Drains were capped 24 hours after TEVAR, for an addi-
tional 24 hours. If no paraparesis developed, the spinal
drain was removed. Rates of spinal drain placement re-
mained constant throughout the study period.
End points and study design. The primary end point
was all-cause mortality at the last follow-up. Decedents at
30 days were included in the definition of late mortality,
and 30-day or in-hospital death was also measured. Causes
of death were defined as (1) cardiac (MI, arrhythmia,
CHF), (2) stroke or spinal cord injury, (3) pulmonary
(pneumonia, acute respiratory distress syndrome, or pneu-
mothorax), (4) renal failure, (5)malignancy, (6)mesenteric
ischemia, (7) thoracic aortic rupture after TEVAR, (8)
infrarenal aortic aneurysm rupture, and (9) other.
The effect of medical comorbidities, laboratory values,
and medication use upon actuarial estimated all-cause mor-
tality was evaluated among the entire cohort that under-
went TEVAR, and patients who presented without rup-
ture, pain, or other symptoms. The second subgroup was
analyzed to exclude patients with known causes of leuko-
cytosis (WBC count 10  103/L), such as mycotic
aneurysms, other infections, oncologic, or hematologic
disorders, thereby isolating the effect of leukocytosis on
mortality.
Statistical analysis. Descriptive statistics are pre-
sented as mean  standard deviation for continuous data
and frequencies and percentages for categoric data. Thirty-
day mortality was evaluated using descriptive statistics pre-
sented as frequencies and percentages. All-cause mortality
was evaluated using survival analysis and Cox proportional
hazards regression. Hazard ratios (HR) are presented with
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multivariate modeling were selected based on P .10, and
statistical significance was assessed based on the log-rank
test at an   0.05. Actuarial survival estimates are pre-
sented as mean  standard error. Data were analyzed
with SPSS 16.0 software (SPSS Inc, Chicago, Ill), and
SigmaPlot (SYSTAT Software Inc, Chicago, Ill).
RESULTS
Demographics and technical details. Between De-
cember 1998 and February 2009, 252 patients (149 men),
who were a mean age of 68 years, underwent TEVAR at
Emory University Hospital. Presentation was degenerative
thoracic aortic aneurysm (TAA) in 143 (103 asymptomatic),
type B dissection in 62 (14 acute), mycotic aneurysm in 13,
traumatic pseudoaneurysm in 12, penetrating ulcer or intra-
mural hematoma in 10, anastomotic pseudoaneurysm in 4, or
other pathology in 8. Decedents at last follow-up had an
increased prevalence of COPD, CAD, PAD, history of to-
bacco abuse, MI, stroke, and coronary revascularization. Pa-
tients presenting with larger aneurysms, rupture, or requiring
concurrent debranching procedures were also more prevalent
among the decedents (Table I).
The mean diameter of the aneurysm was 62.1  17.6
mm. Endografts included 192 TAG (77%), 24 Talent (10%),
15 Valiant (6%), and 8 TX2 (3%). The remaining 13 patients
(4%) received various combinations of endografts or custom
grafts that were modified at the time of use. Concurrent
debranching procedures were done in 19% of patients, com-
prising 17 carotid subclavian artery bypasses, 8 proximal arch
debranching procedures, and 22 visceral debranching proce-
dures. Only 2 of the 47 debranching procedures were staged,
with laboratory data assessed before the initial debranching
procedure. A single endograft component was used in 107
patients (43%), 83 (33%) required two components, and 62
(24%) required three or more components. Lumbar drains
were used in 51 patients (20%), and 31 (12%) required iliac
conduits for access (Fig 1).
Morbidity and all-cause mortality at 30 days and at
last known follow-up. Mortality was 9.5% at 30 days, and
all-cause mortality at the last-known follow-up was 35%. Car-
diac causes of deathwere highly prevalent at 30 days and at the
last known follow-up. The most frequent causes and sub-
groups with the highest mortality rate at 30 days are listed in
Tables II and III, respectively. Stroke or spinal cord injury
occurred in 5.6% of patients. Mean follow-up was 22  22
months. Estimated mean survival was 53.5  3.7 months.
Approximately 50% of patients died 52 months, and
causes of late death are summarized in Table II. Patients
who underwent elective repair of asymptomatic, unrup-
tured TAA had the lowest latemortality rate, with a Kaplan-
Meier mean survival of 55.7 5.1 months. Poorer survival
was documented in patients presenting with mycotic aneu-
rysms, anastomotic aneurysms, or other undefined pathol-
ogies, including Kommerell diverticulum (n  2), “float-
ing” aortic thrombi (n  4), or aortic coarctation (n  1).
Univariate and multivariate analyses. Variables that
were associated with an increased risk of all-cause mortality byunivariate analysis (P  .1) included age, preoperative serum
albumin, WBC count, hemoglobin, serum creatinine, aneu-
rysm diameter, COPD, cardiac arrhythmia, ruptured pathol-
ogy at presentation, or need for concurrent debranching.
Factors that were associated with a decreased risk of all-cause
mortality were statin use, -blocker use, and hypercholester-
olemia. A multivariate Cox proportional hazards model re-
vealed that ruptured pathology at presentation (HR, 3.10;
95% CI, 1.02-9.44; P  .03), debranching (HR, 2.20; 95%
CI, 1.09-4.24;P .03), preoperativeWBCcount (HR, 1.23;
95% CI, 1.09-1.39; P .001), and aneurysm diameter (HR,
1.02; 95% CI, 1.01-1.03; P  .04) were independent
predictors of death (Table IV). Stratification of the total
TEVAR cohort by WBC count higher or lower than 10.0 
103 cells/L demonstrates the association of preopera-
tive WBC count with all-cause late mortality (P .0001,
Table I. Patient demographics
Variablea
Status at follow-up
Alive
(n  163)
Dead
(n  89)
Age, y 67  11 70  13
Male 88 (54) 61 (69)
Baseline laboratory values
Serum albumin, g/dL 3.3  0.5 3.1  0.6
White blood cell count, 103/L 7.7  2.6 8.6  3.1
Hemoglobin, g/dL 12.6  1.7 12.1  2.1
Platelet count, 103/L 237  100 244  109
Serum creatinine, mg/dL 1.5  1.7 1.4  1.1
Medical comorbidities
COPD 36 (23) 30 (35)
Smoking history 66 (42) 49 (56)
Current 32 (20) 25 (29)
Coronary artery disease 56 (35) 39 (45)
History of coronary revascularization 30 (18) 29 (33)
Congestive heart failure 16 (10) 6 (7)
History of myocardial infarct 20 (13) 15 (17)
History of cardiac arrhythmia 13 (8) 15 (17)
History of stroke 12 (8) 11 (13)
Peripheral arterial disease 29 (18) 24 (27)
Dialysis-dependent renal failure 4 (3) 4 (5)
Hypertension 137 (86) 66 (76)
Hyperlipidemia 59 (37) 28 (32)
Diabetes mellitus 30 (19) 13 (15)
History of cancer 23 (14) 16 (18)
Medications
Statin 63 (39) 27 (30)
ACE inhibitors 46 (28) 22 (35)
-blockers 89 (55) 35 (39)
Antiplatelet agents 52 (32) 39 (44)
Aortic-related factors
Baseline aneurysm diameter, mm 59  14 68  20
Symptoms at presentation 70 (43) 39 (44)
Rupture 13 (8) 27 (30)
Concurrent debranching 25 (15) 22 (25)
Prior infrarenal aortic repair 26 (16) 18 (20)
Concurrent infrarenal aneurysm 25 (15) 8 (9)
ACE, Angiotensin-converting enzyme; COPD, chronic obstructive pulmo-
nary disease.
All continuous variables are presented as mean  standard deviation. All
categoric variables are presented as the number or frequency and per-
centage (%).log-rank, Fig 2, A).
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WBC count (HR, 1.19; 95% CI, 1.01-1.40; P  .04), and
aneurysm diameter (HR, 1.03; 95% CI, 1.01-1.05; P .01)
remained predictive of all-cause late mortality in subgroup
analysis of asymptomatic patients with nonruptured TAA
(Table V). Stratification of asymptomatic patients by WBC
count higher or lower than 10 103 cells/L illustrates the
association betweenWBC count and all-cause mortality (P
.005, log rank; Fig 2, B). No difference in actuarial-estimated
survival was observed between patients undergoing arch de-
branching procedures or visceral artery debranching proce-
dures.
DISCUSSION
TEVAR has expanded therapy for thoracic aortic dis-
ease to a broad patient population with significant comor-
bid conditions that would otherwise preclude open surgical
Fig 1. Distribution of aortic pathologies treated by thoracic en-
dovascular aortic repair between December 1998 and February
2009.
Table II. Causes of death at 30 days and at the last
follow-up
Cause of death
30 days
(n  24)
30 days
(n  65)
No. (%) No. (%)
Cardiac 4 (18) 12 (18)
Stroke/spinal cord ischemia 3 (13) 2 (3)
Pulmonary 6 (25) 4 (6)
Renal failure 2 (8) 1 (2)
Malignancy 0 (0) 6 (9)
Mesenteric ischemia 2 (8) 2 (3)
Failed exclusion of thoracic
aortic rupturea
7 (29) 0 (0)
Infrarenal aneurysm rupture 0 (0) 3 (5)
Otherb 0 (0) 4 (6)
Unknown 3 (13) 29 (45)
aPatients presenting with ruptured thoracic aortic pathology who could not
successfully be excluded by thoracic endovascular aortic repair.
bFailure to thrive (n  2), tracheoinnominate fistula (n  1), and lower
gastrointestinal bleeding (n  1).repair. However, strategies to improve patient selection arerequired to identify those patients who would be least likely
to benefit from intervention. More than half of all patients
died 5 years of treatment, with rupture, concurrent de-
branching, aneurysm diameter, and leukocytosis identified
as risk factors for all-cause mortality at last-known follow-
up. Leukocytosis, aneurysm diameter, and concurrent de-
branching were predictive of death even among those
patients presenting with an asymptomatic TAA.
TEVAR provides an effective strategy for a reduction of
deaths related to thoracic aortic rupture.5-8 The degree to
which this intervention improves overall life expectancy is
uncertain, however. The most frequent causes of late death
in our series after TEVAR included cardiac, pulmonary, or
neoplastic etiologies, or rupture of a concomitant infrarenal
aortic aneurysm. The presence of underlying pathophysio-
Table III. Baseline and postoperative characteristics
associated with the highest 30-day mortality
Characteristic No.
Decedents
No. (%)a
All patients 252 24 (9.5)
Elective asymptomatic TAA 103 5 (4.9)
Baseline
Baseline WBC 10  103 cells/L 65 14 (22)
Ruptured at presentation 40 10 (25)
Concurrent debranching procedure 47 7 (15)
Symptomatic at presentation 111 15 (14)
Baseline serum creatinine 1.7 mg/dL 41 5 (12)
Postoperative variables
Cardiac event 16 10 (63)
Dialysis 18 8 (44)
Stroke/spinal chord ischemia 14 5 (36)
TAA, Thoracic aortic aneurysm; WBC, white blood cells.
aThe percentages represent the proportion of decedents in the subgroup.
Table IV. Multivariate all-cause mortality model at the
last known follow-up for the 252 patients who underwent
thoracic endovascular aortic repaira
Variable
Adjusted HR
(95% CI) P
Age 1.01 (0.98-1.03) .89
Serum albumin 0.79 (0.47-1.57) .86
White blood cell count 10 103/L 1.20 (1.08-1.32) .01
Hemoglobin 0.93 (0.78-1.11) .42
Serum creatinine 1.7 mg/dL 1.87 (0.95-3.68) .07
COPD 0.94 (0.52-1.71) .85
History of cardiac arrhythmia 1.58 (0.77-3.24) .22
Hypercholesterolemia 0.80 (0.39-1.63) .53
Statin use 0.61 (0.30-1.25) .18
-blocker use 0.88 (0.51-1.53) .65
Baseline aneurysm diameter 1.02 (1.01-1.03) .03
Rupture 2.28 (1.03-3.63) .04
Concurrent debranching procedure 1.93 (1.10-2.91) .02
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
HR, hazard ratio.
aDisplayed candidate covariates were selected based on univariate associa-
tions with mortality (P  .10).logic processes that persist after TEVAR are often common
) TE
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conditions and serve to limit the ability of thoracic aortic
intervention to have a dramatic effect on late survival. Thus,
risk stratification offers an opportunity to identify patients
in whom the survival benefit afforded by TEVAR may be
marginal. Moreover, our findings continue to emphasize
the need for optimal intervention that is appropriately
targeted to these other conditions after TEVAR.
The association between leukocytosis and all-cause
Fig 2. Survival of patients is shown stratified by white blo
for (A) thoracic endovascular aortic repair (TEVR) and (B
Table V. Multivariate mortality model for 103 patients
who underwent thoracic endovascular aortic repair for
asymptomatic, unruptured thoracic aortic aneurysma
Variable
Adjusted HR
(95% CI) P
Age 1.02 (0.98-1.07) .32
Serum albumin 0.99 (0.50-1.93) .97
White blood cell count 10 103/L 3.59 (1.39-9.25) .01
Serum creatinine 1.7 mg/dL 1.46 (0.64-3.34) .38
COPD 0.91 (0.47-1.79) .79
Hypercholesterolemia 0.57 (0.25-1.31) .19
Statin use 0.80 (0.34-1.91) .62
Diabetes mellitus 0.88 (0.30-2.64) .82
Baseline aneurysm diameter 1.03 (1.01-1.06) .01
Concurrent debranching procedure 2.67 (1.26-5.64) .01
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
HR, hazard ratio.
aDisplayed candidate covariates were selected based on univariate associa-
tions with mortality (P  .10).mortality after TEVAR is a provocative finding in ourinvestigation, particularly among patients presenting with
asymptomatic TAA. The observed increase in late all-cause
mortality among patients with leukocytosis is consistent
with prior reports that have evaluated the relationship of
WBC and death among patients presenting with PAD and
CAD. Indeed, leukocytosis is prevalent among patients
with atherosclerotic risk factors, including tobacco use and
increased body mass index, and a statistically significant
association between WBC count and 30-day mortality has
been observed among patients undergoing coronary artery
bypass grafting.15 Although it is likely that an elevated
WBC is indicative of a systemic inflammatory state that
contributes to CAD, further investigation will be required
to determine if this is the primary factor contributing to an
increased risk of late death. If future studies corroborate a
causal link between leukocytosis and death among patients
with thoracic aortic pathology, then treatments with hy-
droxyurea or other agents to decrease the leukocyte count
and reduce the risk of vascular disease morbidity may be of
some benefit.16
Although multiple reports document the feasibility of
debranching in the management of thoracoabdominal pa-
thologies, these adjunctive procedures have been associated
with an increased risk of postoperative morbidity and com-
promised postoperative survival.17,18 Debranching likely
identifies patients with more extensive thoracic pathology.
However, the number of implanted endoprosthetic com-
ponents, as an alternate surrogate marker for extensive
disease, did not correlate with survival. The addition of arch
ell count (WBC) higher or lower than 10 103 cells/L
VR for asymptomatic, nonruptured thoracic aneurysms.od cor visceral vessel debranching may impose a significant
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quences, as suggested by a 30-day mortality of approxi-
mately 15%, and also long-term effects. Our study did not
show a difference between patients undergoing arch or
visceral debranching, although a larger study would be
required to detect a survival difference. Use of branched or
fenestrated endografts may assist in reducing the burden of
this adjunctive procedure.19
The effect of aneurysm diameter is most likely a surrogate
for patients with more extensive aneurysms and a greater
degree of comorbidities. A similar association between aneu-
rysm diameter and death has been shown among patients
undergoing endovascular repair of infrarenal aortic aneu-
rysms.20Our series corroborates the finding that patients with
moremedical risk factors had larger aneurysms. As reported in
Table I, decedents had increased aneurysm size, as well as a
higher percentage of patients with CAD, history of coronary
revascularization or MI, and PAD.
Limitations of this investigation include its retrospective
nature, the absence of a concurrent open surgical group, and
the uncertainty of cause of death in 12% of our patients.
CONCLUSIONS
Despite the limitations, these data suggest that leuko-
cytosis, aneurysm diameter, and a concurrent debranching
procedure were each independently associated with late
mortality after TEVAR. Before systematic changes are im-
plemented in patient selection, further prospective assess-
ment of these factors with larger populations will be re-
quired to confirm their utility in risk-stratification of
patients considered for TEVAR, as well as the development
of new strategies to improve late survival. Current investi-
gations with larger populations undergoing TEVAR are
ongoing to explore the role of these risk factors upon
survival.
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Dr H. Edward Garrett Jr, MD (Memphis, Tenn): I congrat-
ulate you on an excellent presentation and congratulate the Emory
group for a robust experience with thoracic aortic endografting.
This is a retrospective analysis of a single-center experience aimed
at evaluating the risk factors contributing to 30-day and late
mortality following thoracic aortic endografting for a wide variety
of aortic pathologies.
The authors conclude that several factors independently pre-
dict mortality after thoracic endovascular aortic repair (TEVAR) by
multivariate analysis. Of course, it is no surprise that rupture is
associated with increased 30-day mortality. Among elective cases,
concurrent debranching, size of aneurysm, and white count
10,000 were all independent predictors of mortality.
There are multiple reports documenting the increased mor-
bidity and mortality associated with debranching procedures.
Probably this procedure should be reserved for specific individual
situations. Although increased aneurysm diameter correlates with
increased risks, I do not believe that this will change our practice
patterns. In my mind, the patient with the larger aneurysm is the
one most needing urgent repair who I can also offer the most
benefit from repair.
This leaves us with the most intriguing conclusion from this
data: patients with a preoperative white count 10,000 have
increased 30-day and all-cause mortality. This finding has been
previously documented in multiple studies for coronary artery
disease, stroke, and lower extremity ischemia, but to my knowl-
edge (someone can correct me if I am wrong), this is the first
evidence that an elevated white count produces increasedmortality
for thoracic aortic pathology. In the previous reports of increased
morbidity and mortality in coronary, cerebrovascular, and lower
extremity ischemia patients, the elevated white count appeared to
be a marker of systemic inflammation and the mechanism of death
was small vessel thrombosis associated with myocardial infarction
or stroke. It was assumed that an elevated white count was associ-
ated with platelet activation, endothelial dysfunction, compliment
activation, and/or oxidative injury resulting in small vessel throm-
bosis.
It would be very interesting to know, therefore, if an elevated
white count in patients with thoracic aortic pathology resulted in
the same increased risk of myocardial infarction and stroke or was
associated with aneurysm-related complications. Unfortunately,
the cause of death was unknown in 45% of your patients, which is
the most disappointing limitation of this study. In patients with
elevated white count in whom the cause of death was known, whatwas that cause? In addition, it was unclear to me if patients with
mycotic aneurysm or recent trauma (who might be expected to
have an elevated white count) were included in this asymptomatic
subgroup analysis, which may have skewed the interpretation.
Could you clarify this?
So what does this mean for our practice? Should we delay
surgical treatment in patients with an elevated white count? Should
we explore treatment options to actively decrease their white
count? Or is elevated white counts simply a byproduct of obesity
and smoking? In conclusion, will this information change your
clinical practice? I enjoyed the manuscript and appreciated receiv-
ing it in a timely fashion, and I appreciate the privilege of opening
this discussion.
Dr Corriere. Thank you very much for your insightful ques-
tions. We did not specifically model postoperative myocardial
infarction or stroke as outcomes, so I can’t really answer that
question for you at this time. As for specific causes of death, the
majority of deaths (in those patients where a cause could be
ascertained) were due to myocardial infarction; this was the cause
of death in about a third of the patients. Renal failure was another
common cause of death, although as you said, cause of death was
unknown in many cases. There were a subset of patients who
succumbed to complications related to subsequent abdominal
aortic aneurysm repair, and these were counted as aneurysm-
related mortalities. We did not exclude mycotic aneurysms or
aortic repairs related to traumatic injury; although they comprised
a minority of the indications for repair, neither had a significant
univariate association with mortality in this analysis.
What does it mean in our practice? Apart from risk stratifica-
tion, I am not sure. Literature related to leukocytosis in patients
with cardiovascular disease hypothesizes that administration of
hydroxyurea or antagonism of selectin and/or integrin receptors
may be future therapeutic strategies, but I have not observed any
published reports of successful reduction in procedural mortality
or complications resulting from specific therapies of this nature. I
think it is fascinating that there are specific benefits of statin use in
patients with coronary artery disease and leukocytosis. This does
not specifically change management of the majority of patients
undergoing thoracic aortic repair, however, as nearly all these
patients should be on statin medications anyway. To summarize,
the patient with leukocytosis who needs an aortic repair is at
increased risk for mortality, but apart from ruling out or treating
any acute infection, we cannot recommend any other specific
management based on this analysis.
